A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck

Japanese Journal of Clinical Oncology

Volumn 38, Issue 7, 2008, Pages 459-463

  Wang, Tso Fu ^a   Chu, Sung Chao ^a   Kao, Ruey Ho ^a,b   Yao, Chao Yuan ^a   Li, Chi Cheng ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Epirubicin; Head and neck; Paclitaxel; Platinum refractory; Squamous cell carcinoma

Indexed keywords

ANTIBIOTIC AGENT; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; KIDNEY FUNCTION; LIVER FUNCTION; LUNG INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SEPSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DRUG TOXICITY; EPIRUBICIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 48849090380     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn052     Document Type: Article

References (26)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Mendenhall WM, Riggs CE, Cassisi NJ. Cancer: Principles and practice of oncology. In: De Vita V, Hellman S, Rosenberg S, editors. Treatment of Head and Neck Cancers, 7th edn. Philadelphia, PA: Lippincott Williams & Wilkins 2005;662-732.
3. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644-52.
4. Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995;22(Suppl 6):41-6.
5. Forastiere AA, Shank D, Neuberg D, Taylor SGt, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-4.
6. Gebbia V, Testa A, Cannata G, Gebbia N. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer 1996;32A:901-2.
7. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005;17:218-24.
8. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788-856.
9. Conte PF, Michelotti A, Baldini E, Salvadori B, Gennari A, Da Prato M, et al. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Semin Oncol 1996;23(Suppl 11):28-31.
10. Grasselli G, Vigano L, Capri G, Locatelli A, Tarenzi E, Spreafico C, et al. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 2001;19:2222-31.
11. Adamo V, Maisano R, Pergolizzi S, Altavilla G, Caristi N, Chiofalo G, et al. Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Chemother 1997;9:72-6.
12. Paccagnella A, Pappagallo GL, Segati R, Zorat P, Cavaniglia G, Lunghi F, et al. Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. Eur J Cancer 1993;29A:704-8.
13. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-92.
14. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomize d phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2009;26:1642-9.
15. Kohler U, Olbricht SS, Fuechsel G, Kettner E, Richter B, Ridwelski K. Weekly paclitaxel with epirubicin as second-line therupy of metastatic breast cancer: Results of a clinical phase II study. Semin Oncol. 1997;24(Suppi 17):S17-40-S17-43.
16. Nistico C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, et al. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: A phase II study. Anticancer Drugs 2007;18:687-92.
17. Leon X, Hitt R, Constenla M, Rocca A, Stupp R, Kovacs AF, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17:418-24.
18. Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol 2007;37:477-81.
19. Ray-Coquard I, Bachelot T, Guastalla JP, Levy E, Tigaud JD, Vincent P, et al. Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecol Oncol 2003;88:351-7.
20. Koechli OR, Sevin BU, Perras JP, Chou TC, Angioli R, Steren A, et al. Characteristics of the combination paclitaxel plus doxombicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res Treat 1993;28:21-7.
21. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33.
22. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
23. Weizer AZ, Joshi D, Daignault S, Kinnaman M, Hussain M, Montie JE, et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 2007;177: 1287-93.
24. Chen SC, Chang HK, Lin YC, Cheung YC, Tsai CS, Leung WM, et al. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. Onkologie 2005;28:339-44.
25. Hussain M, Kish JA, Crane L, Uwayda A, Cummings G, Ensley JF, et al. The role of infection in the morbidity and mortality of patients with head and neck cancer undergoing multimodality therapy. Cancer 1991;67:716-21.
26. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-77.